ArticleJournal of translational medicine2026
PUF, a biflavone monomer, triggers DNA damage through SLC25A15 downregulation and purine metabolic suppression in DLBCL.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) remains a therapeutic challenge, with a substantial proportion of patients failing to respond to standard regimens. Natural biflavonoids have demonstrated antitumor potential, but their effects on the metabolic vulnerabilities of DLBCL are poorly understood. This study aimed to elucidate the antitumor efficacy and of pulvinatabiflavone (PUF), a novel biflavonoid monomer isolated from Selaginella cuspidata, against DLBCL and the related mechanism.
methodsThe antiproliferative effects of PUF were evaluated in multiple DLBCL cell lines (OCI-LY8, SU-DHL-2, SU-DHL-8, and RIVA) and a xenograft mouse model using CCK-8, flow cytometry (apoptosis/cell cycle), and Western blotting. Metabolomics, transcriptomics, functional rescue experiments (with IMP and dGTP), and SLC25A15 knockdown models were used to investigate the mechanism of PUF.
resultsPUF potently inhibited DLBCL cell proliferation (IC₅₀ < 2 μg/ml at 48 h), induced apoptosis, and caused G2/M cell cycle arrest. Multiomics analyses revealed that PUF disrupted purine nucleotide metabolism, leading to critical dGTP depletion and subsequent DNA damage, as evidenced by increased γ-H2AX expression. This DNA damage was ameliorated by supplementation with the purine metabolites IMP or dGTP. PUF was found to downregulate the mitochondrial transporter SLC25A15, which is highly expressed in DLBCL. Molecular docking and cellular thermal shift assay (CETSA) confirmed that PUF directly binds to the mitochondrial transporter SLC25A15. Knockdown of SLC25A15 ameliorated the DNA damage phenotype, which was similarly rescued by dGTP. Importantly, in the xenograft model, PUF treatment not only suppressed tumor growth but also downregulated SLC25A15 and upregulated γ-H2AX in tumor tissues, confirming the mechanism in vivo.
conclusionsThe biflavonoid PUF exerts profound anti-DLBCL effects by directly targeting SLC25A15, disrupting purine nucleotide metabolism, thereby inducing dGTP shortage-mediated DNA damage. Our integrated findings from in silico, cellular, and animal models suggest that PUF is a promising therapeutic candidate and reveal that SLC25A15 is a novel metabolic target in DLBCL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.